Literature DB >> 33507915

Personalized logical models to investigate cancer response to BRAF treatments in melanomas and colorectal cancers.

Jonas Béal1,2,3, Lorenzo Pantolini1,2,3, Vincent Noël1,2,3, Emmanuel Barillot1,2,3, Laurence Calzone1,2,3.   

Abstract

The study of response to cancer treatments has benefited greatly from the contribution of different omics data but their interpretation is sometimes difficult. Some mathematical models based on prior biological knowledge of signaling pathways facilitate this interpretation but often require fitting of their parameters using perturbation data. We propose a more qualitative mechanistic approach, based on logical formalism and on the sole mapping and interpretation of omics data, and able to recover differences in sensitivity to gene inhibition without model training. This approach is showcased by the study of BRAF inhibition in patients with melanomas and colorectal cancers who experience significant differences in sensitivity despite similar omics profiles. We first gather information from literature and build a logical model summarizing the regulatory network of the mitogen-activated protein kinase (MAPK) pathway surrounding BRAF, with factors involved in the BRAF inhibition resistance mechanisms. The relevance of this model is verified by automatically assessing that it qualitatively reproduces response or resistance behaviors identified in the literature. Data from over 100 melanoma and colorectal cancer cell lines are then used to validate the model's ability to explain differences in sensitivity. This generic model is transformed into personalized cell line-specific logical models by integrating the omics information of the cell lines as constraints of the model. The use of mutations alone allows personalized models to correlate significantly with experimental sensitivities to BRAF inhibition, both from drug and CRISPR targeting, and even better with the joint use of mutations and RNA, supporting multi-omics mechanistic models. A comparison of these untrained models with learning approaches highlights similarities in interpretation and complementarity depending on the size of the datasets. This parsimonious pipeline, which can easily be extended to other biological questions, makes it possible to explore the mechanistic causes of the response to treatment, on an individualized basis.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33507915      PMCID: PMC7872233          DOI: 10.1371/journal.pcbi.1007900

Source DB:  PubMed          Journal:  PLoS Comput Biol        ISSN: 1553-734X            Impact factor:   4.475


  68 in total

1.  Toward Explainable Anticancer Compound Sensitivity Prediction via Multimodal Attention-Based Convolutional Encoders.

Authors:  Matteo Manica; Ali Oskooei; Jannis Born; Vigneshwari Subramanian; Julio Sáez-Rodríguez; María Rodríguez Martínez
Journal:  Mol Pharm       Date:  2019-10-31       Impact factor: 4.939

2.  TANDEM: a two-stage approach to maximize interpretability of drug response models based on multiple molecular data types.

Authors:  Nanne Aben; Daniel J Vis; Magali Michaut; Lodewyk F A Wessels
Journal:  Bioinformatics       Date:  2016-09-01       Impact factor: 6.937

Review 3.  BRAFV600E: implications for carcinogenesis and molecular therapy.

Authors:  Emma R Cantwell-Dorris; John J O'Leary; Orla M Sheils
Journal:  Mol Cancer Ther       Date:  2011-03       Impact factor: 6.261

4.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Authors:  David M Hyman; Igor Puzanov; Vivek Subbiah; Jason E Faris; Ian Chau; Jean-Yves Blay; Jürgen Wolf; Noopur S Raje; Eli L Diamond; Antoine Hollebecque; Radj Gervais; Maria Elena Elez-Fernandez; Antoine Italiano; Ralf-Dieter Hofheinz; Manuel Hidalgo; Emily Chan; Martin Schuler; Susan Frances Lasserre; Martina Makrutzki; Florin Sirzen; Maria Luisa Veronese; Josep Tabernero; José Baselga
Journal:  N Engl J Med       Date:  2015-08-20       Impact factor: 91.245

5.  OncoKB: A Precision Oncology Knowledge Base.

Authors:  Debyani Chakravarty; Jianjiong Gao; Sarah M Phillips; Ritika Kundra; Hongxin Zhang; Jiaojiao Wang; Julia E Rudolph; Rona Yaeger; Tara Soumerai; Moriah H Nissan; Matthew T Chang; Sarat Chandarlapaty; Tiffany A Traina; Paul K Paik; Alan L Ho; Feras M Hantash; Andrew Grupe; Shrujal S Baxi; Margaret K Callahan; Alexandra Snyder; Ping Chi; Daniel Danila; Mrinal Gounder; James J Harding; Matthew D Hellmann; Gopa Iyer; Yelena Janjigian; Thomas Kaley; Douglas A Levine; Maeve Lowery; Antonio Omuro; Michael A Postow; Dana Rathkopf; Alexander N Shoushtari; Neerav Shukla; Martin Voss; Ederlinda Paraiso; Ahmet Zehir; Michael F Berger; Barry S Taylor; Leonard B Saltz; Gregory J Riely; Marc Ladanyi; David M Hyman; José Baselga; Paul Sabbatini; David B Solit; Nikolaus Schultz
Journal:  JCO Precis Oncol       Date:  2017-05-16

6.  Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.

Authors:  Clara Montagut; Sreenath V Sharma; Toshi Shioda; Ultan McDermott; Matthew Ulman; Lindsey E Ulkus; Dora Dias-Santagata; Hannah Stubbs; Diana Y Lee; Anurag Singh; Lisa Drew; Daniel A Haber; Jeffrey Settleman
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

7.  A Landscape of Pharmacogenomic Interactions in Cancer.

Authors:  Francesco Iorio; Theo A Knijnenburg; Daniel J Vis; Graham R Bignell; Michael P Menden; Michael Schubert; Nanne Aben; Emanuel Gonçalves; Syd Barthorpe; Howard Lightfoot; Thomas Cokelaer; Patricia Greninger; Ewald van Dyk; Han Chang; Heshani de Silva; Holger Heyn; Xianming Deng; Regina K Egan; Qingsong Liu; Tatiana Mironenko; Xeni Mitropoulos; Laura Richardson; Jinhua Wang; Tinghu Zhang; Sebastian Moran; Sergi Sayols; Maryam Soleimani; David Tamborero; Nuria Lopez-Bigas; Petra Ross-Macdonald; Manel Esteller; Nathanael S Gray; Daniel A Haber; Michael R Stratton; Cyril H Benes; Lodewyk F A Wessels; Julio Saez-Rodriguez; Ultan McDermott; Mathew J Garnett
Journal:  Cell       Date:  2016-07-07       Impact factor: 41.582

Review 8.  Molecular targeted therapy of BRAF-mutant colorectal cancer.

Authors:  Michel Ducreux; Ali Chamseddine; Pierre Laurent-Puig; Cristina Smolenschi; Antoine Hollebecque; Peggy Dartigues; Emmanuelle Samallin; Valérie Boige; David Malka; Maximiliano Gelli
Journal:  Ther Adv Med Oncol       Date:  2019-06-18       Impact factor: 8.168

Review 9.  Resistant mechanisms to BRAF inhibitors in melanoma.

Authors:  José Luís Manzano; Laura Layos; Cristina Bugés; María de Los Llanos Gil; Laia Vila; Eva Martínez-Balibrea; Anna Martínez-Cardús
Journal:  Ann Transl Med       Date:  2016-06

Review 10.  Negative feedback regulation of the ERK1/2 MAPK pathway.

Authors:  David Lake; Sonia A L Corrêa; Jürgen Müller
Journal:  Cell Mol Life Sci       Date:  2016-06-24       Impact factor: 9.261

View more
  4 in total

Review 1.  Boolean modelling as a logic-based dynamic approach in systems medicine.

Authors:  Ahmed Abdelmonem Hemedan; Anna Niarakis; Reinhard Schneider; Marek Ostaszewski
Journal:  Comput Struct Biotechnol J       Date:  2022-06-17       Impact factor: 6.155

2.  Patient-specific Boolean models of signalling networks guide personalised treatments.

Authors:  Julio Saez-Rodriguez; Laurence Calzone; Arnau Montagud; Jonas Béal; Luis Tobalina; Pauline Traynard; Vigneshwari Subramanian; Bence Szalai; Róbert Alföldi; László Puskás; Alfonso Valencia; Emmanuel Barillot
Journal:  Elife       Date:  2022-02-15       Impact factor: 8.713

Review 3.  Navigating Multi-Scale Cancer Systems Biology Towards Model-Driven Clinical Oncology and Its Applications in Personalized Therapeutics.

Authors:  Mahnoor Naseer Gondal; Safee Ullah Chaudhary
Journal:  Front Oncol       Date:  2021-11-24       Impact factor: 6.244

4.  Model-checking ecological state-transition graphs.

Authors:  Colin Thomas; Maximilien Cosme; Cédric Gaucherel; Franck Pommereau
Journal:  PLoS Comput Biol       Date:  2022-06-06       Impact factor: 4.779

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.